The groundbreaking success of the copyright undeniably revolutionized the drug landscape, but placing funds in companies primarily reliant on generic versions presents a challenging picture. Although early profits were significant, the end of patents and the appearance of less expensive alternatives have weakened sales. Therefore, a thorough evalua